Drummond Michael, Barbieri Marco, Cook John, Glick Henry A, Lis Joanna, Malik Farzana, Reed Shelby D, Rutten Frans, Sculpher Mark, Severens Johan
Centre for Health Economics, University of York, York, UK.
Value Health. 2009 Jun;12(4):409-18. doi: 10.1111/j.1524-4733.2008.00489.x. Epub 2009 Jan 12.
ABSTRACT A growing number of jurisdictions now request economic data in support of their decision-making procedures for the pricing and/or reimbursement of health technologies. Because more jurisdictions request economic data, the burden on study sponsors and researchers increases. There are many reasons why the cost-effectiveness of health technologies might vary from place to place. Therefore, this report of an ISPOR Good Practices Task Force reviews what national guidelines for economic evaluation say about transferability, discusses which elements of data could potentially vary from place to place, and recommends good research practices for dealing with aspects of transferability, including strategies based on the analysis of individual patient data and based on decision-analytic modeling.
摘要 现在，越来越多的司法管辖区要求提供经济数据，以支持其关于卫生技术定价和/或报销的决策程序。由于更多的司法管辖区要求提供经济数据，研究发起者和研究者的负担增加了。卫生技术的成本效益可能因地区而异，原因有很多。因此，这份由药物经济学与结果研究国际协会（ISPOR）良好实践工作组撰写的报告回顾了经济评估的国家指南中关于可转移性的内容，讨论了哪些数据元素可能因地区而异，并推荐了处理可转移性方面问题的良好研究实践，包括基于个体患者数据分析和基于决策分析模型的策略。
